Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients

Journal of Hospital Infection

Volumn 40, Issue SUPPL. B, 1998, Pages

  Herwaldt, L A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

CAPD patients; Dialysis patients; Mupirocin; Nasal carriage; Rifampicin; Staphylococcus aureus infections

Indexed keywords

BACITRACIN; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CARRIER; DRUG HYPERSENSITIVITY; HEMODIALYSIS PATIENT; HUMAN; INFECTION RISK; INTRANASAL DRUG ADMINISTRATION; META ANALYSIS; MORBIDITY; MORTALITY; NOSE; ORAL DRUG ADMINISTRATION; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; TOPICAL DRUG ADMINISTRATION;

EID: 0031726091     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-6701(98)90200-6     Document Type: Conference Paper

References (38)

1. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Arch Intern Med 1989; 149: 1258-1262.
2. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. N Engl J Med 1986; 315: 91-96.
3. Dobkin JF, Miller MH, Steigbigel NH. Septicemia in patients on chronic hemodialysis. Ann Int Med 1978; 88: 28-33.
4. Quarles LD, Rutsky EA, Rostand SG. Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 1985; 6: 412-419.
5. Barcenas CG, Fuller TJ, Elms J, Cohen R, White MG. Staphylococcal sepsis in patients on chronic hemodialysis regimens: intravenous treatment with vancomycin given once weekly. Arch Int Med 1976; 136: 1131-1134.
6. Mennes PA, Gilula LA, Anderson CB, Etheredge EE, Weerts H, Harter HR. Complications associated with arteriovenous fistulas in patients undergoing chronic hemodialysis. Arch Int Med 1978; 138: 1117-1121.
7. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG. A prospective study of infections in hemodialysis patients: patient hygiene and other risk factors for infection. Infect Control Hosp Epidemiol 1988; 9: 534-541.
8. Francioli P, Masur H. Complications of Staphylococcus aureus bacteremia: occurrence in patients undergoing long-term hemodialysis. Arch Int Med 1982; 142: 1655-1658.
9. Mathews M, Shen FH, Lindner A, Sherrard DJ. Septic arthritis in hemodialysis patients. Nephron 1980; 25: 87-91.
10. Moxley GF, Moffatt TL, Falls WF Jr. Hemodialysis-related osteomyelitis. South Med J 1980; 73: 376-379.
11. Nsouli KA, Lazarus M, Schoenbaum SC, Gottlieb MN, Lowrie EG, Shocair M. Bacteremic infection in hemodialysis. Arch Int Med 1979; 139: 1255-1258.
12. Holton DL, Nicolle LE, Diley D, Bernstein K. Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic haemodialysis patients. J Hosp Infect 1991; 17: 133-137.
13. Bommer J, Vergetis W, Andrassy K, Hingst V, Borneff M, Huber W. Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J 1995; 41: 127-131.
14. Watanakunakorn C, Brandt J, Durkin P, Santore S, Bota B, Stahl CJ. The efficacy of mupirocin ointment and chlorhexidine body scrubs in the eradication of nasal carriage of Staphylococcus aureus among patients undergoing long-term hemodialysis. Am J Infect Control 1992; 20: 138-141.
15. Kluytmans JAJW, Manders M-J, van Bommel E, Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996; 17: 793-797.
16. Boelaert JR, van Landuyt HW, Gordts BZ, de Baere YA, Messer SA, Herwaldt LA. Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. Infect Control Hosp Epidemiol 1996; 17: 809-811.
17. Boelaert JR, de Smedt RA, de Baere YA et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 278-281.
18. Boelaert JR, van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235-239.
19. Fong IW. Prevention of haemodialysis and peritoneal dialysis catheter related infection by topical povidone-iodine. Postgrad Med J 1993; 69: S15-S17.
20. Kirmani N, Tuazon CU, Murray HW, Parrish AE, Sheagren JN. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138: 1657-1659.
21. Ena J, Boelaert JR, Boyken LD, van Landuyt HW, Godard CA, Herwaldt LA. Epidemiology of Staphylococcus aureus infections in patients on hemodialysis. Infect Control Hosp Epidemiol 1994; 15: 78-81.
22. Martin AM, Clunie GJA, Tonkin RW, Robson JS. The aetiology and management of shunt infections in patients on intermittent haemodialysis. Proc Eur Dial Transplant Assoc 1967; 4: 67-72.
23. Masano H, Fukuchi K, Wakuta R, Tanaka Y. Efficacy of intranasal application of povidoneiodine cream in eradicating nasal methicillin-resistant Staphylococcus aureus in neonatal intensive care unit (NICU) staff. Postgrad Med J 1993; 69: S122-S125.
24. Davies SJ, Ogg CS, Cameron JS, Poston S, Noble WC. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Pent Dial Int 1989; 9: 61-64.
25. Sewell CM, Clarridge J, Lacke C, Weinman EJ, Young EJ. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA 1982; 248: 1493-1495.
26. Sesso R, Draibe S, Castelo A et al. Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1989; 31: 264-268.
27. Wanten GJA, van Oost P, Schneeberger PM, Koolen MI. Nasal carriage and peritonitis by Staphylococcus aureus in patients on continuous ambulatory peritoneal dialysis: a prospective study. Perit Dial Int 1996; 16: 352-356.
28. Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis-related infections. Perit Dial Int 1994; 14: 137-144.
29. Luzar MA, Coles GA, Faller B et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322: 505-509.
30. Piraino B, Perlmutter JA, Holley JL, Bernardini J. Staphylococcus aureus peritonitis is associated with Staphylococcus aureus nasal carriage in peritoneal dialysis patients. Perit Dial Int 1992; 13: S332-S334.
31. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27: 695-700.
32. Perez-Fontan M, Garcia-Falcon T, Rosales M et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. Am J Kidney Dis 1993; 22: 708-712.
33. Perez-Fontan M, Rosales M, Rodriguez-Carmona A et al. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992; 8: 242-245.
34. Lye WC, Leong SO, van der Straaten J, Lee EJC. Staphylococcus aureus CAPD-related infections are associated with nasal carriage. Adv Perit Dial 1994; 10: 163-165.
35. Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis, J Am Soc Nephrol 1996; 7: 2403-2408.
36. Pignatari A, Pfaller M, Hollis R, Sesso R, Lerne I, Herwaldt L. Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol 1990; 28: 1898-1902.
37. Zimmerman SW, Ahrens E, Johnson CA et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991; 18: 225-231.
38. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis 1996; 27: 687-694.